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Introduction: Diabetes mellitus (DM (Diabetes Mellitus)) is directly associated with some cancers.
However, studies on the association between diabetes mellitus and head and neck cancer (HNC (Head
and Neck Cancer)) have rendered controversial results. The objective of this study was to evaluate the
association between DM and HNC, as well as the impact of metformin use on the risk of HNC.
Material and methods: This case-control study was conducted within the framework of the Brazilian Head
and Neck Genome Project in 2011–2014. The study included 1021 HNC cases with histologically con-
firmed squamous cell carcinoma of the head and neck admitted to five large hospitals in São Paulo state.
A total of 1063 controls were selected in the same hospitals. Odds ratios (OR) and 95% confidence inter-
vals (CI) were estimated using unconditional logistic regression.
Results: Diabetic participants had a decreased risk of HNC (OR = 0.68; 95% CI: 0.49–0.95) than non-
diabetic participants, and this risk was further decreased among diabetic metformin users (OR = 0.54;
95% CI: 0.29–0.99). Diabetic metformin users that were current smokers (OR = 0.13; 95% CI: 0.04–0.44)
or had an alcohol consumption of >40 g/day (OR = 0.31; 95% CI: 0.11–0.88) had lower risk of HNC than
equivalent non-diabetic participants.
Conclusion: The risk of HNC was decreased among diabetic participants; metformin use may at least par-
tially explain this inverse association.
 2016 Elsevier Ltd. All rights reserved.Introduction
Head and neck cancer (HNC) includes tumours of the oral cav-
ity, oropharynx, hypopharynx, and larynx. Nasopharyngeal cancer
is also a HNC sub-site but is usually considered a separate diseasewith a distinct aetiology and particular characteristics [1]. Approx-
imately 600,000 cases of HNC are diagnosed each year, and HNC
accounts for 4% of cancer mortality worldwide [2]. More than
90% of HNC are squamous cell carcinoma [3]. The main risk factors
associated with HNC are smoking and alcohol consumption, and
the interaction between these factors can increase the risk of
HNC [4]. Other risk factors include poor oral health, diet, genetic
factors, low body mass index (BMI), and occupational factors [5–8].
The association between diabetes mellitus (DM) and the
increased risk of certain cancers, such as liver, pancreatic, colon,
kidney, bladder, endometrial, and breast cancer, is well established
[9–11], while the risk of prostate cancer is decreased among dia-
betic patients [11,12]. Although some studies with DM has also
Table 1




Missing anatomical location of tumor 126
Missing morphology information 50
Cancer diagnosis not confirmed 34
Cancer at other sites (not HNC) 21
Others histology (not SCC) 12
Cancer in situ 9
Synchronous cancers 7
Previous cancer treatment 4
Cancers with previous HNC treatment 3
Repeat cases 3




Did not meet inclusion criteria 36
With cancer diagnosis 13
Repeated controls 3
Total controls 1115
HNC: head and neck cancer; SCC: squamous cell carcinoma.
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some studies, diabetic patients had an increased risk of cancer at
some HNC sub-sites [10,13–15], while in other studies this risk
was decreased [9,16].
One possible explanation for inverse association between DM
and some kinds of cancers is metformin use among diabetic
patients. Metformin is a medication used to control Type 2 DM
and can inhibit cell proliferation, which has been inversely associ-
ated with cancer risk [11,17]. It has been shown that metformin
users have a reduced risk of colorectal, liver, lung, and prostate
cancer [18–20]. Studies on the association between DM and the
risk of HNC that take into account metformin use have also
reported conflicting results. A Taiwanese study reported a
decreased risk of HNC among metformin users (adjusted hazard
ratio = 0.66; 95% confidence interval [CI] 0.55–0.79) [21], while
another study in the United Kingdom reported no association [22].
The objective of this study was to evaluate the association
between DM and HNC, as well as the impact of metformin use
on the risk of HNC.Material and methods
This case-control study was conducted within the framework of
the Brazilian Head and Neck Genome Project (GENCAPO) from
December 2011 to November 2014. The study recruited 1291
HNC cases admitted to three general hospitals and two cancer hos-
pitals in Sao Paulo state, Brazil. All HNC cases had histologically
confirmed squamous cell carcinoma of the head and neck, and
the International Classification of Diseases, 10th Revision [23]
was used to classify these cancers into five sub-sites [24]: oral cav-
ity, oropharynx, hypopharynx, larynx, and oral-oropharynx-
hypopharynx not specified.
A total of 1115 controls were selected from the same hospitals
as the HNC cases: in the general hospitals we recruited hospital
controls who were individuals admitted with diseases other than
cancer (for example, diseases related to skin, eyes, ears, genitouri-
nary tract, circulatory disorders, nervous system disorders and
others); visitor controls were recruited in the cancer hospitals,
excluding visitors of HNC patients, since they could have similar
habits to the HNC patients.
After exclusions, the final study sample comprised 1021 cases
and 1063 controls (Table 1). Controls were frequency-matched toHNC cases by sex and age (in 5-year groups). This study was
approved by the institutional ethical review boards of all hospitals,
and all participants gave written informed consent.
Data collection
Participants were interviewed using a standardised question-
naire to collect information on socio-demographic, socio-
economic, and lifestyle factors, as well as family history of cancer.
Authors extracted information on age, sex, education, BMI (based
on height and weight 2 years before the interview), DM, tobacco
consumption, and alcohol consumption from the questionnaire.
Blood samples were also collected from cases and controls,
stored in tubes containing EDTA at 70 C, and used for glycated
haemoglobin tests (A1C). A1C provides an average assessment of
glucose control for the previous 60–90 days without the need for
fasting. A1C was performed using 1 ml of blood at a laboratory cer-
tified by the National Glycohemoglobin Standardization Program
and was considered positive for diabetes when values were above
6.5% [25].
The final DM variable was constructed by combining informa-
tion from three sources in order to ensure a better characterisation
of the main explanatory variable and avoid underestimating the
prevalence of DM. Thus, participants who reported they were dia-
betic at interview, or had a diagnosis of DM in medical records, or
had a positive A1C result were categorised as diabetic (Table 2).
Patients with self-reported DM were categorised as diabetic even
if A1C values were below 6.5% (controlled DM). Diabetic partici-
pants were then further categorised as metformin users and non-
users. Information about metformin use was taken from medical
records.
Tobacco consumption was assessed in pack-years, calculated by
multiplying the average number of packs of cigarettes smoked in
1 day by the number of years the participant smoked. One cigar-
ette, one pipe and one cigar are equivalent to 1 g, 3.5 g and 4 g of
tobacco, respectively. Analyses were performed for both smoking
status and pack-years of tobacco consumption.
Alcohol consumption was assessed in g/day. One litter of differ-
ent alcoholic beverages was converted to 5%, 12%, and 40% of alco-
hol for beer, wine, and spirits, respectively. Consumption was then
converted to grams of alcohol (one litter is equivalent to 798 g of
alcohol) and the daily average alcohol intake during the consump-
tion period was calculated. Analyses were performed for both
drinking status and g/day of alcohol consumption.
Statistical analysis
Odds ratios (OR) and 95% CI were estimated using uncondi-
tional logistic regression. Analyses comparing participants with
and without DM were adjusted for sex, age, education, BMI (in
kg/m2), tobacco consumption, and alcohol consumption. The mod-
els were also adjusted for hospital of recruitment (centre), since
heterogeneity was detected by the likelihood ratio-test.
In metformin analyses, diabetic metformin users and non-users
were compared with those without DM. However, these analyses
did not include controls who were visitors in cancer hospitals.
Indeed, as they were not patients they did not have medical
records available in which to verify metformin use. Consequently,
metformin analyses were not adjusted for centre.
Analyses were stratified by sex, HNC sub-site, smoking status,
drinking status, tobacco consumption (non-smokers, >0–40, >40
pack-years) and alcohol consumption (non-drinkers, >0–40,
>40 g/day).
Missing data were found for the following variables: education
(18 cases and two controls), BMI (86 cases and five controls), alco-
hol consumption (50 cases and 20 controls), and tobacco consump-
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PROC MI procedure in version 9.4 of SAS statistical software (SAS
Institute, Inc., Cary, North Carolina) was applied in order to include
participants with missing data in the analyses. Estimated power for
the study was 86.8%. For analysis using metformin information,
calculated power was 77.1%. All statistical analyses were con-
ducted using SAS version 9.4 statistical software and a 5% statisti-
cal significance level was adopted.Results
Among the 1021 cases and 1063 controls, a higher percentage of
current-smokers were observed in cases (68.0%) compared to con-
trols (16.3%). Of cases, 53.6% were current-drinkers compared with
43.5% of controls. There were 359 participants with DM, 150Table 2
Selected characteristics of the study sample by case/control status.
Sex Male
Female
Education No formal education


















Alcohol drinking status Non-drinker
Former drinker
Current drinker







Type of hospital General hospital
Cancer hospital
Presence of DM No
Yes








BMI: body mass index; DM: diabetes mellitus; HNC: head and neck cancer.(14.7%) cases and 209 (19.7%) controls. A large percentage
(18.7%) of diabetic participants was identified through A1C only.
DM was inversely associated with HNC in both males and
females and in all HNC sub-sites (Table 3). However, the risk reduc-
tion was statistically significant only in males (OR = 0.68; 95% CI:
0.47–0.99) and in pharyngeal cancer (OR = 0.43; 95% CI: 0.27–
0.68). The decreased risk of HNC associated with DM was most
remarkable among heavy smokers (>40 pack-years) and heavy
drinkers (>40 g/day) (Table 4).
In analyses considering use of metformin were included 1021
cases and 587 hospital controls, only those in which it was possible
to confirm or not the use of metformin. So visitor controls who did
not have metformin information were excluded from the analysis.
Metformin use among diabetic participants was associated with a
decreased risk of HNC. A negative association was also observed in
patients with pharyngeal and laryngeal cancer (Table 5), as well asCases Controls
n % n %
884 86.6% 693 65.2%
137 13.4% 370 34.8%
136 13.6% 74 7.0%
581 57.9% 473 44.6%
137 13.7% 162 15.3%
119 11.9% 239 22.5%
30 3.0% 113 10.7%
48 5.1% 25 2.4%
536 57.3% 379 36.3%
252 27.0% 375 35.9%
99 10.6% 266 25.5%
76 7.5% 525 49.7%
249 24.5% 360 34.1%
690 68.0% 172 16.3%
76 7.5% 525 49.7%
61 6.0% 196 18.5%
65 6.4% 95 9.0%
104 10.2% 63 6.0%
128 12.6% 57 5.4%
135 13.3% 44 4.2%
453 44.6% 106 10.0%
84 8.7% 353 33.8%
367 37.8% 236 22.6%
520 53.6% 454 43.5%
84 8.7% 353 33.8%
87 9.0% 291 27.9%
52 5.4% 121 11.6%
46 4.7% 63 6.0%
51 5.3% 45 4.3%
46 4.7% 29 2.8%
605 62.3% 141 13.5%
429 42.0% 587 55.2%
592 57.9% 476 44.8%
871 85.3% 854 80.3%







n Mean (SD) n Mean (SD)
1021 59 (10.2) 1063 56.3 (12.9)
980 68.7 (14.1) 1058 75.2 (16.6)
Table 3
Odds ratios (OR) and confidence intervals (CI) of the association between diabetes mellitus (DM) and risk of head and neck cancer (HNC) for all participants and stratified by sex
and HNC sub-site.
Cases Controls p-value OR 95% CI
n % n %
All individualsa (n = 1021) (n = 1063)
Without DM 871 85.3% 854 80.3% 0.022 1
With DM 150 14.7% 209 19.7% 0.68 (0.49–0.95)
By sexb
Male (n = 884) (n = 693)
Without DM 758 85.7% 554 79.9% 0.042 1
With DM 126 14.3% 139 20.1% 0.68 (0.47–0.99)
Female (n = 137) (n = 370)
Without DM 113 82.5% 300 81.1% 0.532 1
With DM 24 17.5% 70 18.9% 0.80 (0.39–1.63)
By HNC sub-sitea
Oral cavity (n = 349) (n = 1063)
Without DM 288 82.5% 854 80.3% 0.221 1
With DM 61 17.5% 209 19.7% 0.75 (0.48–1.19)
Pharynx (oropharynx + hypopharynx) (n = 390) (n = 1063)
Without DM 345 88.5% 854 80.3% <0.001 1
With DM 45 11.5% 209 19.7% 0.43 (0.27–0.68)
Larynx (n = 214) (n = 1063)
Without DM 175 81.8% 854 80.3% 0.465 1
With DM 39 18.2% 209 19.7% 0.83 (0.51–1.37)
a OR adjusted for age, sex, body mass index, tobacco, alcohol and centre.
b OR adjusted for age, body mass index, tobacco, alcohol and centre.
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drinkers (OR = 0.31; 95% CI: 0.11–0.88) (Table 6).
Although there is no sufficient statistical power to perform sep-
arate analysis for oropharyngeal and hypopharyngeal cancer, an
exploratory analysis indicated a lower risk of hypopharyngeal can-
cer in diabetic metformin users. The risk of oropharyngeal cancer
was decreased in both metformin users and non-users (data not
shown).
Discussion
In this case-control study was found an inverse association
between DM and HNC. This association was also observed in sub-
groups such as men, current smokers, heavy drinkers, and partici-
pants with pharyngeal and laryngeal cancer. A possible
explanation for this decreased risk could be metformin use in par-
ticipants with DM. Indeed, metformin users in our study had the
lowest risk of HNC, and a decreased risk of HNC was also observed
in metformin users who were current smokers or heavy drinkers.
This study has several strengths, including the availability of
A1C results for most participants. Indeed, if authors had used
self-reported information only, as has been done in other studies,
a considerable percentage of cases (30.5%) and controls (28%)
would have been wrongly classified as not having DM, and the
observed association between DM and HNC would have been
biased. However, the study also has limitations. Controls who were
visitors in cancer hospitals were excluded from metformin analy-
ses, since they did not have medical records in which were possible
verify metformin use. Moreover, as in other studies, we were
unable to separate DM by type (Type 1 or Type 2), as this informa-
tion was missing for 33.3% of cases and 25.8% of controls. Although
metformin is mostly used in Type 2 DM, metformin use in individ-
uals with Type 1 DM has increased in recent years, as it may lead to
contribute to a decrease in the daily dose of insulin [26]. In present
study, metformin was used by five (27.8%) of the 18 participants
with Type 1 DM. Although it is important, as in the most studies
evaluating the association between metformin, DM and cancer,
the present study could not be adjusted for dosage or duration ofmetformin use since this information was present only for 5% of
DM individuals.
Previous studies on the association between DM and HNC sub-
sites have shown contradictory results [9,10,13–16,27]. Findings in
the current study were similar to those from the SEER database for
people over 68 years old (OR = 0.92; 95% CI: 0.88–0.96) [16] and
those of a study on men (OR = 0.85 for cancer of the oral cavity +
pharyngeal cancer, 95% CI: 0.82–0.89; OR = 0.76 for laryngeal can-
cer, 95% CI: 0.71–0.80) [9]. In agreement with current study, some
previous studies have reported a decreased cancer risk amongmet-
formin users. However, the protective effect of metformin use on
HNC is not conclusive [21,22]. Sikka et al. [28] demonstrated that
metformin may inhibit cell growth in squamous cell carcinoma
of the head and neck. Thus the protection conferred by metformin
use may be explained by its role in the activation of adenosine
monophosphate-activated protein kinase (AMPK) [19,29]. AMPK
is an enzyme and its activation inhibits protein synthesis and the
action of the mTOR protein. mTOR is important for cell growth
and its activity is deregulated in various cancers [19,30]. The mTOR
pathway is regulated by both AMPK and AKT, which have opposite
functions. In response to an external stimulus, AKT activates the
mTOR pathway, contributing to cell proliferation. On the other
hand, the AMPK can reduce the action of mTOR. Metformin use
may activate AMPK, thus inhibiting mTOR action and decreasing
cell proliferation [11,19,31].
Persistent activation of AKT is present in various cancers,
including HNC [32]. Although tobacco and alcohol consumption
are the main risk factors for HNC, the molecular mechanism
involved is not clear and few studies have investigated the associ-
ation between these risk factors and AKT and mTOR activation,
especially in HNC. One study showed that alcohol and tobacco acti-
vate AKT [33]. Another study showed that NKK, a main tobacco car-
cinogen, is associated with activation of AKT in HNC patients [34].
Likewise, tobacco promotes lung tumorigenesis through activation
of signalling the AKT/mTOR pathway [35].
Present results indicated that DM was inversely associated with
HNC in current smokers and heavy smokers, though this inverse
association was restricted to metformin users. The present study
Table 4
Odds ratios (OR) and confidence intervals (CI) of head and neck cancer (HNC) according to diabetes mellitus (DM) by level of tobacco and alcohol consumption.
Cases Controls p-value ORa 95% CI
n % n %
Smoking statusa
Non-smoker (n = 75) (n = 525)
Without DM 62 82.7% 433 82.5% 0.926 1
With DM 13 17.3% 92 17.5% 1.04 (0.50–2.16)
Former smoker (n = 249) (n = 360)
Without DM 187 75.1% 272 75.6% 0.966 1
With DM 62 24.9% 88 24.4% 1.01 (0.63–1.62)
Current smoker (n = 690) (n = 172)
Without DM 619 89.7% 145 84.3% 0.003 1
With DM 71 10.3% 27 15.7% 0.42 (0.24–0.74)
Drinking statusb
Non-drinker (n = 84) (n = 353)
Without DM 70 83.3% 278 78.8% 0.086 1
With DM 14 16.7% 75 21.2% 0.47 (0.20–1.11)
Former drinker (n = 367) (n = 236)
Without DM 309 84.2% 185 78.4% 0.927 1
With DM 58 15.8% 51 21.6% 1.03 (0.58–1.82)
Current drinker (n = 520) (n = 454)
Without DM 448 86.2% 374 82.4% 0.159 1
With DM 72 13.8% 80 17.6% 0.71 (0.45–1.14)
Tobacco consumption (in pack-years)a
Non-smoker (n = 75) (n = 525)
Without DM 62 82.7% 433 82.5% 0.926 1
With DM 13 17.3% 92 17.5% 1.04 (0.50–2.16)
0–40 (n = 351) (n = 382)
Without DM 303 86.3% 306 80.1% 0.400 1
With DM 48 13.7% 76 19.9% 0.81 (0.50–1.32)
>40 (n = 588) (n = 150)
Without DM 503 85.5% 111 74.0% 0.002 1
With DM 85 14.5% 39 26.0% 0.44 (0.26–0.74)
Alcohol consumption (in g/day)b
Non-drinker (n = 84) (n = 353)
Without DM 70 83.3% 278 78.8% 0.086 1
With DM 14 16.7% 75 21.2% 0.47 (0.20–1.11)
0–40 (n = 236) (n = 520)
Without DM 194 82.2% 427 82.1% 0.775 1
With DM 42 17.8% 93 17.9% 0.93 (0.55–1.57)
>40 (n = 651) (n = 170)
Without DM 563 86.5% 132 77.6% 0.027 1
With DM 88 13.5% 38 22.4% 0.56 (0.33–0.94)
a OR adjusted for age, sex, body mass index, alcohol and centre.
b OR adjusted for age, sex, body mass index, tobacco and centre.
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users who were heavy smokers. Metformin use has been reported
to prevent tobacco carcinogen-induced lung tumorigenesis in ani-
mal models [36]. Indeed, metformin has been suggested as a
chemopreventive agent against lung cancer among heavy smokers
[37]. The mechanism of metformin may be similar in HNC and lung
cancer, since the main risk factor for both is tobacco smoke.
Our study is the first to investigate the association between
metformin use and HNC in diabetic individuals who are heavy
drinkers. A decreased risk of HNC is not entirely surprising consid-
ering the literature on animal models. In one study, a group of rats
with chronic ethanol consumption showed a reduction in AMPK
enzyme, but the group with ethanol consumption and treated with
metformin showed improvement in hepatic injury through activa-
tion of AMPK. The AMPK level was similar in rats without met-
formin and without alcohol consumption [38]. Among heavy
alcohol drinkers, the protective effect for HNC observed in diabetic
metformin users might be explained by activation of AMPK bymetformin, but further studies should carried out to evaluate and
understand this mechanism.
We observed an inverse association between HNC and DM in all
metformin users, but the associations were only statistically signif-
icant for laryngeal cancer. Becker et al. [22] also reported a reduc-
tion in the risk of laryngeal cancer in long-term metformin users.
Results also showed an inverse association between pharyngeal
cancer and DM, regardless of metformin use. Despite the lack of
statistical power to study oropharyngeal and hypopharyngeal can-
cer separately, the results indicated a reduced risk of hypophary-
geal cancer among diabetic metformin users. All diabetic
participants had a reduced risk of oropharyngeal cancer regardless
of metformin use. In a pooled analysis, no association was found
between DM and cancer of the oropharynx or other HNC sub-
sites [27]. It is noteworthy that pharyngeal cancers are different
from laryngeal cancers in pathogenesis and prognosis [3,39], which
can explain differences in results. Although the incidence of both
oropharyngeal and laryngeal cancer are higher in men, there is a
Table 5
Odds ratios (OR) and confidence intervals (CI) of head and neck cancer (HNC) according to diabetes mellitus (DM) and metformin use for all participants and stratified by sex and
HNC sub-site.
Cases Controls p-value OR 95% CI
n % n %
All individualsa (n = 1021) (n = 587)
Without DM 871 85.3% 470 80.1% 0.067 1
DM and metformin 40 3.9% 48 8.2% 0.049 0.54 (0.29–0.99)
DM without metformin 110 10.8% 69 11.8% 0.142 0.72 (0.46–1.12)
By sexb
Male (n = 885) (n = 322)
Without DM 758 85.7% 257 79.8% 0.089 1
DM and metformin 33 3.7% 25 7.8% 0.073 0.51 (0.24–1.07)
DM without metformin 93 10.5% 40 12.4% 0.134 0.67 (0.39–1.13)
Female (n = 137) (n = 265)
Without DM 113 82.5% 213 80.4% 0.828 1
DM and metformin 7 5.1% 23 8.7% 0.577 0.74 (0.26–2.11)
DM without metformin 17 12.4% 29 10.9% 0.744 0.88 (0.40–1.91)
HNC sub-sitea
Oral cavity (n = 349) (n = 587)
Without DM 288 82.5% 470 80.1% 0.429 1
DM and metformin 22 6.3% 48 8.2% 0.365 0.72 (0.36–1.46)
DM without metformin 39 11.2% 69 11.8% 0.293 0.74 (0.42–1.30)
Pharynx (oropharynx + hypopharynx) (n = 390) (n = 587)
Without DM 345 88.5% 470 80.1% 0.002 1
DM and metformin 11 2.8% 48 8.2% 0.023 0.34 (0.13–0.86)
DM without metformin 34 8.7% 69 11.8% 0.004 0.41 (0.22–0.75)
Larynx (n = 214) (n = 587)
Without DM 175 81.8% 470 80.1% 0.049 1
DM and metformin 7 3.3% 48 8.2% 0.019 0.28 (0.10–0.81)
DM without metformin 32 15.0% 69 11.8% 0.655 1.16 (0.60–2.26)
a OR adjusted for age, sex, body mass index, tobacco and alcohol.
b OR adjusted for age, body mass index, tobacco and alcohol.
Table 6
Odds ratios (OR) and confidence intervals (CI) of head and neck cancer (HNC) according to diabetes mellitus (DM) and metformin use by smoking and drinking status and
consumption level of tobacco and alcohol.
Cases Controls p-value OR 95% CI
n % n %
Smoking statusa
Non smoker (n = 75) (n = 307)
Without DM 62 82.7% 246 80.1% 0.421 1
DM and metformin 6 8.0% 29 9.4% 0.443 0.68 (0.25–1.83)
DM without metformin 7 9.3% 32 10.4% 0.250 0.57 (0.22–1.49)
Former smoker (n = 249) (n = 178)
Without DM 187 75.1% 138 77.5% 0.903 1
DM and metformin 20 8.0% 14 7.9% 0.854 0.92 (0.40–2.14)
DM without metformin 42 16.9% 26 14.6% 0.711 1.13 (0.59–2.15)
Current smoker (n = 690) (n = 197)
Without DM 619 89.7% 83 85.6% 0.003 1
DM and metformin 13 1.9% 5 5.2% 0.001 0.13 (0.04–0.44)
DM without metformin 58 8.4% 9 9.3% 0.269 0.61 (0.26–1.46)
Drinking statusb
Non drinker (n = 84) (n = 238)
Without DM 70 83.3% 185 77.7% 0.118 1
DM and metformin 5 6.0% 25 10.5% 0.274 0.53 (0.17–1.66)
DM without metformin 9 10.7% 28 11.8% 0.061 0.39 (0.15–1.05)
Former drinker (n = 367) (n = 143)
Without DM 309 84.2% 112 78.3% 0.818 1
DM and metformin 14 3.8% 11 7.7% 0.541 0.72 (0.26–2.05)
DM without metformin 44 12.0% 20 14.0% 0.934 1.03 (0.49–2.19)
Current drinker (n = 520) (n = 189)
Without DM 448 86.2% 159 84.1% 0.841 1
DM and metformin 21 4.0% 12 6.3% 0.572 0.74 (0.27–2.08)
DM without metformin 51 9.8% 18 9.5% 0.818 0.91 (0.41–2.02)
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Table 6 (continued)
Cases Controls p-value OR 95% CI
n % n %
Tobacco consumption (in pack-years)a
Non-smoker (n = 75) (n = 307)
Without DM 62 82.7% 246 80.1% 0.421 1
DM and metformin 6 8.0% 29 9.4% 0.443 0.68 (0.25–1.83)
DM without metformin 7 9.3% 32 10.4% 0.250 0.57 (0.22–1.49)
0–40 (n = 351) (n = 209)
Without DM 303 86.3% 172 82.3% 0.164 1
DM and metformin 13 3.7% 13 6.2% 0.065 0.42 (0.17–1.06)
DM without metformin 35 10.0% 24 11.5% 0.816 1.08 (0.56–2.10)
>40 (n = 588) (n = 66)
Without DM 503 85.5% 49 74.2% 0.718 1
DM and metformin 20 3.4% 6 9.1% 0.066 0.36 (0.12–1.07)
DM without metformin 65 11.1% 11 16.7% 0.104 0.53 (0.25–1.14)
Alcohol consumption (in g/day)b
Non-drinker (n = 84) (n = 238)
Without DM 70 83.3% 185 77.7% 0.118 1
DM and metformin 5 6.0% 25 10.5% 0.274 0.53 (0.17–1.66)
DM without metformin 9 10.7% 28 11.8% 0.061 0.39 (0.15–1.05)
0–40 (n = 236) (n = 248)
Without DM 194 82.2% 203 81.9% 0.924 1
DM and metformin 15 6.4% 16 6.5% 0.704 1.21 (0.46–3.16)
DM without metformin 27 11.4% 29 11.7% 0.958 0.98 (0.48–2.00)
>40 (n = 651) (n = 84)
Without DM 563 86.5% 68 81.0% 0.036 1
DM and metformin 20 3.1% 7 8.3% 0.028 0.31 (0.11–0.88)
DM without metformin 68 10.4% 9 10.7% 0.571 0.78 (0.34–1.83)
a OR adjusted for age, sex, body mass index and alcohol.
b OR adjusted for age, sex, body mass index and tobacco.
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in some European countries [2,39,40]. Unlike the laryngeal cancer,
an increase in oropharyngeal incidence has occurred in whites and
younger individuals [39]. There is growing evidence that a substan-
tial proportion of oropharyngeal cancers are associated with
human papillomavirus (HPV) infection [39,40]. Unfortunately,
there was no information on HPV in our study; therefore this infor-
mation was not added in the models, which could have caused
some bias in the results for oropharyngeal cancer.
Conclusion
We found an inverse association between DM and HNC. The
protective effect of DM was at least partially explained by met-
formin use, since metformin users had an even lower risk of
HNC. The inverse association of HNC risk among metformin users




The authors would like to thank the members of the GENCAPO
(Brazilian Head and Neck Genome Project) and São Paulo Research
Foundation (FAPESP). The study was supported by FAPESP (grant
2010/51168-0, 2013/20548-0, 2013/21702-3 and 2014/18893-4).
References
[1] Pezzuto F, Buonaguro L, Caponigro F, Ionna F, Starita N, Annunziata C, et al.
Update on head and neck cancer: current knowledge on epidemiology, risk
factors, molecular features and novel therapies. Oncology 2015;89:125–36.
http://dx.doi.org/10.1159/000381717.[2] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer
incidence and mortality worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer 2015;136:359–86. http://dx.doi.org/10.1002/
ijc.29210.
[3] Gao J, Panizza B, Johnson NW, Coman S, Clough AR. Basic consideration of
research strategies for head and neck cancer. Front Med 2012;6:339–53.
http://dx.doi.org/10.1007/s11684-012-0213-7.
[4] Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al.
Interaction between tobacco and alcohol use and the risk of head and neck
cancer: pooled analysis in the International Head and Neck Cancer
Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev
2009;18:541–50. http://dx.doi.org/10.1158/1055-9965.EPI-08-0347.
[5] Ahrens W, Pohlabeln H, Foraita R, Nelis M, Lagiou P, Lagiou A, et al. Oral health,
dental care and mouthwash associated with upper aerodigestive tract cancer
risk in Europe: the ARCAGE study. Oral Oncol 2014;50:616–25. http://dx.doi.
org/10.1016/j.oraloncology.2014.03.001.
[6] Conway DI, Brenner DR, Mcmahon AD, Macpherson LMD, Agudo A, Ahrens W,
et al. Estimating and explaining the effect of education and income on head
and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control
studies from 27 countries. Int J Cancer 2015;136:1125–39. http://dx.doi.org/
10.1002/ijc.29063.
[7] Delahaye-Sourdeix M, Oliver J, Timofeeva MN, Gaborieau V, Johansson M,
Chabrier A, et al. The 12p13.33/RAD52 locus and genetic susceptibility to
squamous cell cancers of upper aerodigestive tract. PLoS ONE 2015;10:1–12.
http://dx.doi.org/10.1371/journal.pone.0117639.
[8] Lubin JH, Gaudet MM, Olshan AF, Kelsey K, Boffetta P, Brennan P, et al. Body
mass index, cigarette smoking, and alcohol consumption and cancers of the
oral cavity, pharynx, and larynx: modeling odds ratios in pooled case-control
data. Am J Epidemiol 2010;171:1250–61. http://dx.doi.org/10.1093/aje/
kwq088.
[9] Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer
in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011;128:635–43.
http://dx.doi.org/10.1002/ijc.25362.
[10] Bosetti C, Rosato V, Polesel J, Levi F, Talamini R, Montella M, et al. Diabetes
mellitus and cancer risk in a network of case-control studies. Nutr Cancer
2012;64:643–51. http://dx.doi.org/10.1080/01635581.2012.676141.
[11] Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr
Relat Cancer 2009;16:1103–23. http://dx.doi.org/10.1677/ERC-09-0087.
[12] Bansal D, Bhansali A, Kapil G, Krishna U, Tiwari P. Type 2 diabetes and risk of
prostate cancer: a meta-analysis of observational studies. Prostate Cancer
Prostatic Dis 2013;16:151–8. http://dx.doi.org/10.1038/pcan.2012.40.
[13] Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites
among Japanese men and women. Eur J Cancer Prev 2007;16:83–9. http://dx.
doi.org/10.1097/01.cej.0000228404.37858.40.
54 R.A.O Figueiredo et al. / Oral Oncology 61 (2016) 47–54[14] Nakamura K, Wada K, Tamai Y, Tsuji M, Kawachi T, Hori A, et al. Diabetes
mellitus and risk of cancer in Takayama: a population-based prospective
cohort study in Japan. Cancer Sci 2013;104:1362–7. http://dx.doi.org/
10.1111/cas.12235.
[15] Tseng KS, Lin C, Lin YS, Weng SF. Risk of head and neck cancer in patients with
diabetes mellitus: a retrospective cohort study in Taiwan. JAMA Otolaryngol –
Head Neck Surg 2014;140:746–53. http://dx.doi.org/
10.1001/jamaoto.2014.1258.
[16] Stott-Miller M, Chen C, Schwartz SM. Type II diabetes and metabolic syndrome
in relation to head and neck squamous cell carcinoma risk: a SEER-Medicare
database study. Cancer Epidemiol 2013;37:428–33. http://dx.doi.org/10.1016/
j.canep.2013.03.006.
[17] Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA,
et al. Diabetes and cancer: a consensus report. Diabetes Care
2010;33:1674–85. http://dx.doi.org/10.2337/dc10-0666.
[18] Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, et al. Reduced risk of
colorectal cancer with metformin therapy in patients with type 2 diabetes: a
meta-analysis. Diabetes Care 2011;34:2323–8. http://dx.doi.org/10.2337/
dc11-0512.
[19] Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated
with metformin: a systematic review and meta-analysis. PLoS ONE
2012;7:1–9. http://dx.doi.org/10.1371/journal.pone.0033411.
[20] Tseng CH. Metformin may reduce breast cancer risk in Taiwanese woman with
type 2 diabetes. Breast Cancer Res Treat 2014;145:785–90. http://dx.doi.org/
10.1007/s00592-014-0562-6.
[21] Yen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of
head and neck cancer in diabetics. Head Neck 2014;37:1268–73. http://dx.doi.
org/10.1002/hed.23743.
[22] Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of head and
neck cancer: a case-control analysis. Diabetes Obes Metab 2014;16:1148–54.
http://dx.doi.org/10.1111/dom.12351.
[23] World Health Organization. International Statistical Classification of Diseases
and Related Health Problems. 10th Revision. 2nd ed; 2005.
[24] Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al.
Alcohol drinking in never users of tobacco, cigarette smoking in never
drinkers, and the risk of head and neck cancer: pooled analysis in the
international head and neck cancer epidemiology consortium. J Natl Cancer
Inst 2007;99:777–89. http://dx.doi.org/10.1093/jnci/djk179.
[25] American Diabetes Association. Diagnosis and classification of diabetes
mellitus. Diabetes Care 2014;37:81–90. http://dx.doi.org/10.2337/dc14-S081.
[26] Liu C, Wu D, Zheng X, Li P, Li L. Efficacy and safety of metformin for patients
with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther
2015;17:142–8. http://dx.doi.org/10.1089/dia.2014.0190.
[27] Stott-Miller M, Chen C, Chuang SC, Lee YC, Boccia S, Brenner H, et al. History of
diabetes and risk of head and neck cancer: a pooled analysis from the
international head and neck cancer epidemiology consortium. CancerEpidemiol Biomarkers Prev 2012;21:294–304. http://dx.doi.org/10.1158/
1055-9965.EPI-11-0590.
[28] Sikka a, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth
of human head and neck squamous cell carcinoma via global inhibition of
protein translation. Cell Cycle 2012;11:1374–82. http://dx.doi.org/10.4161/
cc.19798.
[29] Musi N, HirshmanMF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al.
Metformin increases AMP-activated protein kinase activity in skeletal muscle
of subjects with type 2 diabetes. Diabetes 2002;51:2074–81.
[30] Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J,
Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget
2011;2:896–917.
[31] Bhat A, Sebastiani G, Bhat M. Systematic review: preventive and therapeutic
applications of metformin in liver disease. World J Hepatol 2015;7:1652–9.
http://dx.doi.org/10.4254/wjh.v7.i12.1652.
[32] Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J,
et al. Persistent activation of the Akt pathway in head and neck squamous cell
carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;10:4029–37.
http://dx.doi.org/10.1158/1078-0432.CCR-03-0249.
[33] Islam MR, Ellis IR, Macluskey M, Cochrane L, Jones SJ. Activation of Akt at T308
and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to
support a prognostic or diagnostic role? Exp Hematol Oncol 2014;3:1–9.
http://dx.doi.org/10.1186/2162-3619-3-25.
[34] Weber SM, Bornstein S, Li Y, Malkoski SP, Wang D, Rustgi AK, et al. Tobacco-
specific carcinogen nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone induces AKT activation in head and neck epithelia. Int J Oncol
2011;39:1193–8. http://dx.doi.org/10.3892/ijo.2011.1149.
[35] Memmott RM, Dennis PA. The role of the Akt/mTOR pathway in tobacco
carcinogen-induced lung tumorigenesis. Clin Cancer Res 2010;16:4–10. http://
dx.doi.org/10.1158/1078-0432.CCR-09-0234.
[36] Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA.
Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer
Prev Res 2010;3:1066–76. http://dx.doi.org/10.1158/1940-6207.CAPR-10-
0055.
[37] Antonoff MB, D’Cunha J. Teaching an old drug new tricks: metformin as a
targeted therapy for lung cancer. Semin Thorac Cardiovasc Surg
2010;22:195–6. http://dx.doi.org/10.1053/j.semtcvs.2010.10.015.
[38] Zhu Z, Jiang Z, Zhou J, Zhou D, Wang W, Zhao C, et al. Involvement of insulin
resistance in the protective effect of metformin against alcoholic liver injury.
Alcohol Clin Exp Res 2014;38:1510–9. http://dx.doi.org/10.1111/acer.12418.
[39] Rettig EM, D’Souza G. Epidemiology of head and neck cancer. Surg Oncol Clin N
Am 2015;24:379–96. http://dx.doi.org/10.1016/j.soc.2015.03.001.
[40] Simard EP, Torre LA, Jemal A. International trends in head and neck cancer
incidence rates: differences by country, sex and anatomic site. Oral Oncol
2014;50:387–403. http://dx.doi.org/10.1016/j.oraloncology.2014.01.016.
